X0306 4 2014-08-22 0 0001009356 SALIX PHARMACEUTICALS LTD SLXP 0001314760 Forbes William P 8510 COLONNADE CENTER DRIVE RALEIGH NC 27615 0 1 0 0 EVP Research&Devel & CDO Common Stock 2014-08-22 4 A 0 19809 158.30 A 119220 D Option to Buy Common Stock 17.53 2014-12-16 Common Stock 11200 11200 D Option to Buy Common Stock 17.63 2015-06-09 Common Stock 6250 6250 D In connection with the transaction contemplated by the Agreement and Plan of Merger, dated as of July 8, 2014, by and among Salix Pharmaceuticals, Ltd. ("Salix"), Cosmo Pharmaceuticals S.p.A., Cosmo Technologies Limited and Sangiovese, LLC (the "Transaction"), the Board of Directors of Salix approved special grants (the "Special Grants") of restricted stock to directors and eligible employees, including William P. Forbes (the "Reporting Person"), intended to lessen the potential tax burden that would be triggered upon the completion of the Transaction. The reported transaction specified in this Form 4 consists solely of the shares of restricted stock granted to the Reporting Person pursuant to the Special Grants. Options are 100% vested. /s/ Donald R. Reynolds, by Power of Attorney 2014-08-26